9-(4-Cyclohexyloxyphenyl)-7-Methyl-3,4-Dihydropyrazino[2,1-C][1,2,4]Thiadiazine 2,2-Dioxide

5 trials 5 recruiting

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

5 Recruiting

0 Completed trials

1 Sponsors

16 Countries

Phase III

Phase III: 5

Sponsors using this IMP

Neurocrine Biosciences Inc. 5

All trials

5 total

Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519423-24-00 Phase III 16 countries Neurocrine Biosciences Inc.
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519420-25-00 Phase III 4 countries Neurocrine Biosciences Inc.
Study to assess the maintenance of effect of NBI-1065845 as an adjunctive treatment in participants with Major Depressive Disorder (MDD) Recruiting

2025-520541-72-00 Phase III 5 countries Neurocrine Biosciences Inc.
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519418-29-00 Phase III 3 countries Neurocrine Biosciences Inc.
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting

2024-519421-37-00 Phase III 4 countries Neurocrine Biosciences Inc.

Showing 1–5 of 5 trials

← All drugs A–Z